Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][3]. Group 1: Allegations Against Sana Biotechnology - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [3]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [3]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [3]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is May 20, 2025, and there is no cost or obligation to participate [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [4]. - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and fraud, emphasizing the importance of responsible business practices [5].
May 20, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SANA